Purpose. The purpose of this study was to examine the effects of Baduanjin sequential therapy (BST) on the quality of life and cardiac function in patients with AMI after PCI. Subjects. 96 patients with AMI after PCI were randomly assigned as subjects to two groups: BST group who received 24 weeks of BST training and control group who received no training. Methods. The methods used in this study included the changes in SF-36 subscales, the measures of left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), the body mass index (BMI), and the abdominal circumference. Results. Of the 96 participants, 82 total patients completed the entire study. At 12 weeks, role physical and health transition of SF-36 were significantly different between the two groups, with a difference of 26.12 (95% CI, 11.59 to 40.64) in role physical and a difference of 15.94 (95% CI, 5.60 to 26.28) in health transition (p<0.05). However, there were statistically significant differences in all aspects of SF-36 between the two groups at 24 weeks (p<0.05). The BST also lowered abdominal circumference and BMI as compared with the control group. In the 24-week follow-up, a significant difference was found in the decline of the LVEF in the control group (p=0.020), while there was a nonsignificant difference in the BST group (p=0.552). Compared with the control group, the BST group reduced 50 pg/ml on the NT-pro-BNP at 24 weeks (p=0.013). The effects of BST exercise were maintained at 24 weeks after the intervention. No serious adverse events were observed. Conclusions. The BST appears to improve the quality of life in patients with AMI after PCI, with additional benefits of lowered abdominal circumference and BMI and improved level of cardiac function. This trial is registered with NCT02693795.

Rationale:Seated-Baduanjin as adjuvant rehabilitation treatment in a patient with Dysfunctional ventilatory weaning response(DVWR) is extremely rare, and we report a case of a patient's rehabilitation exercise who suffered from DVWR.Patient concerns:A 62-year-old patient was admitted for dyspnea for more than a month after surgery.Diagnoses:On arrival, the patient was conscious but anxious, and he had difficulty breathing. When attempting to disconnect the ventilator, the patient's autonomous respiration > 25 times /min, and the heart rate > 120 times /min. He had to rely on the ventilator to survive. According to the characteristics of the patient, we considered the patient with DVWR.Interventions:We provided the same essential treatment as the last hospital and performed the Seated-Baduanjin for the patient which was a new form of bed exercise, 2 times a day, 30 minutes each time.Outcomes:The patient showed a gradual improvement in breathing and muscle strength.Lessons:In this case report, the Seated-Baduanjin showed a remarkable therapeutic effect on a patient and might be an adjuvant treatment for DVWR.

Objective: To study the clinical significance of the change of residual cancer burden (RCB) of epithelial ovarian carcinoma (EOC) between primary (PDS) and interval debulking surgery (IDS) in order to evaluate the effectiveness of adjuvant chemotherapy. Methods: Thirty-eight EOC patients with suboptimal PDS with adjuvant chemotherapy were selected for this retrospective study and divided into pathologically negative (group A) and pathologically positive (group B) groups based on the histopathological examination and the change of size of residual disease after IDS. Patients in group B were further divided into groups B1 (partial remission criteria, n = 9), B2 (consistent with stable disease, n = 12) and B3 (consistent with disease progression, n = 4) based on the changes in RCB between PDS and IDS and the guidelines to evaluate the response to treatment in solid tumors (Response Evaluation Criteria in Solid Tumors, RECIST). The responses to chemotherapy evaluated by pathological examination of RCB versus by CA-125, recurrence patterns, and prognoses were analyzed. Results: The clinical benefit rates evaluated by pathological assessment for groups A, B1, B2 and B3 were 100, 100, 100 and 0%, respectively (p < 0.01), whereas the rates were not statistically different when evaluated by CA-125 (100, 100, 91.7 and 100%, respectively; p > 0.05). The median progression-free survival (PFS) for patients in groups A and B was 36 and 6 months, respectively (p < 0.05); the median overall survival (OS) was 93 and 42 months, respectively (p < 0.05). There were no significant differences in median PFS or OS among patients in groups B1, B2 and B3 (PFS: 16, 6 and 1.5 months; OS: 52, 31 and 30.5 months, respectively; all p > 0.05), but there were significant differences in median PFS or OS between B1 and B3. There was no significant difference in recurrence rates between groups A and B (53.8 vs. 72.0%, p > 0.05), but there were significant differences in the rate of drug-resistant recurrence [28.6% (2/7) vs. 72.2% (13/18), p < 0.05] and in median PFS of relapsed patients (19 vs. 4 months, p < 0.05). Conclusion: The histopathological assessment of RCB between PDS and IDS may be used to evaluate and predict the response to adjuvant chemotherapy in EOC.

BACKGROUND Acute myocardial infarction (AMI) is a serious type of coronary artery disease (CAD) with the potential for substantial morbidity and mortalit. Percutaneous coronary intervention (PCI) is an effective treatment. However, most patients still suffer from angina pectoris, anxiety, depression and reduced cardiac function after PCI. OBJECTIVE The purpose of this study was to examine the effects of Baduanjin sequential therapy (BST) on the quality of life and cardiac function in patients with AMI after PCI. METHODS The study was a randomized controlled trial. Patients with AMI after PCI randomly assigned to a BST group (N = 48) or a control group (N = 48). The BST exercise consists of the sitting and standing forms. The sitting Baduanjin was conducted twice a day in the hospital, for 30 min/session. After the patient was discharged from the hospital, the standing Baduanjin was performed fifth weekly, lasting up to 24-weeks, for 30 min/session. The control group received usual care without Baduanjin. The primary outcomes were the changes of SF-36 subscales. Secondary outcomes included measures of left ventricular ejection fraction(LVEF), N-terminal pro B-type natriuretic peptide (NT-pro-BNP), the Body Mass Index (BMI) and the abdominal circumference. RESULTS Of the 96 participants, 82 total patients completed the entire study. At 12 weeks, Role Physical and Health Transition of SF-36 were significantly different between the two groups, with a difference of 26.12 [95% CI, 11.59 to 40.64] in Role physical and a difference of 15.94 [95% CI, 5.60 to 26.28] in Health Transition (p<0.05). However, there were statistically significant differences in all aspects of SF-36 between the two groups at 24 weeks (p<0.05). The BST also lowered the abdominal circumference and BMI as compared with control group. In the 24-week follow-up, a significant difference was found in the decline of the LVEF in control group (p=0.020),while there was non-significant difference in the BST group (p=0.552). Compared with control group, the BST group reduced 50pg/ml on the NT-Pro-BNP at 24 weeks(p=0.013). The effects of BST exercise were maintained at 24weeks after the intervention. No serious adverse events were observed. CONCLUSIONS The BST appears to improve the quality of life in patients with AMI, with additional benefits of lowered the abdominal circumference and BMI and improved the level of cardiac function. CLINICALTRIAL Clinical Trials.gov:NCT02693795. https://clinicaltrials.gov/ct2/ show/NCT02693795?term=NCT02693795&rank=1.